Kavita Iyer

免疫疗法正在推动精准肿瘤学的发展，但现有的免疫肿瘤学疗法并非对每位患者都有效。我们对转化研究布局的综述揭示了哪些靶点和疗法在临床试验中展现出了良好的前景。

全球制药专利数据揭示了过去五年该领域正在经历根本性转型：治疗平台呈倍数增长，分子靶点已远超传统蛋白质范畴，疾病关注点也正转向以往难以攻克的病症。这些模式不仅展示了创新

Hantavirus, a rodent-borne RNA virus with case fatality rates up to 40%, is reshaping zoonotic disease risk amid environmental change and global mobility.

Vector-borne diseases are spreading to new regions as climate change intensifies, and public health systems need more treatment options to limit the impacts.

With the advent of genetic editing technology, researchers are increasingly able to address immuno-compatibility issues, getting closer to making organs and tissues available for transplant from animal donors to human recipients.

小分子 PPI 抑制剂即将改善癌症治疗

Concept co-occurrence analysis shows the newest ideas in scientific discovery and drives innovation in immuno-oncology.

PROTACs are driving small molecule drug development to treat cancer, neurodegenerative diseases and more

最近举行的癌症与大数据专家网络研讨会揭示了免疫肿瘤学的新兴趋势、数据挑战以及研究人员面临的机遇。

在本文中揭示免疫肿瘤学出版物和研究领域的新趋势，确定未来的新机遇和挑战。